Erin J. Aiello Bowles, MPH

Articles by Erin J. Aiello Bowles, MPH

Utilization of HER2 Genetic Testing in a Multi-Institutional Observational Study

ByKatrina A.B. Goddard, PhD,Erin J. Aiello Bowles, MPH,Heather Spencer Feigelson, PhD, MPH,Laurel A. Habel, PhD,Sharon Hensley Alford, PhD,Catherine A. McCarty, PhD, MPH,Larissa Nekhlyudov, MD, MPH,Adedayo A. Onitilo, MD, MSCR, FACP,Alanna K. Rahm, PhD, MS,Jennifer A. Webster, MS

November 20th 2012

Evaluation of real-world implementation of HER2 testing showed that uptake was high (>90%) and trastuzumab treatment was targeted to patients with positive HER2 status.

Timing of Follow-up After Abnormal Screening and Diagnostic Mammograms

ByKaren J. Wernli, PhD,Erin J. Aiello Bowles, MPH,Sebastien Haneuse, PhD,Joanne G. Elmore, MD, MPH,Diana S.M. Buist, PhD, MPH

March 4th 2011

Woman-level characteristics such as breast symptoms at mammography are associated with earlier follow-up within an integrated health system with an active breast health plan.

Latest Updated Articles

Timing of Follow-up After Abnormal Screening and Diagnostic Mammograms
March 4th 2011
Utilization of HER2 Genetic Testing in a Multi-Institutional Observational Study
November 20th 2012

Erin J. Aiello Bowles, MPH

Articles by Erin J. Aiello Bowles, MPH

Utilization of HER2 Genetic Testing in a Multi-Institutional Observational Study

Timing of Follow-up After Abnormal Screening and Diagnostic Mammograms

Latest Updated Articles

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access